0000000000012685

AUTHOR

Anselm K. Gitt

showing 5 related works from this author

Impact of prehospital delay on mortality in patients with acute myocardial infarction treated with primary angioplasty and intravenous thrombolysis.

2001

Abstract Background In patients with acute myocardial infarction treated with thrombolysis, longer times to treatment are associated with increasingly worse clinical outcome. This relation may be different for treatment with primary angioplasty. Methods We analyzed the pooled data of the German acute myocardial infarction registries Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) and Myocardial Infarction Registry (MIR) to determine the influence of prehospital delays on hospital mortality rates. Primary angioplasty was performed in 1063 patients and thrombolysis in 7552 patients. Results In patients treated with thrombolysis, in-hospital time to treatment was constantly 3…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentTime to treatmentPrimary angioplastyMyocardial InfarctionStatistics NonparametricInternal medicineFibrinolysismedicineHumansIn patientThrombolytic TherapyMyocardial infarctionHospital MortalityProspective StudiesRegistriesChemotherapyChi-Square Distributionbusiness.industryMortality rateThrombolysisMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty BalloonAmerican heart journal
researchProduct

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry

2017

Abstract Introduction The appropriate strategy for initiating oral anticoagulant (OAC) therapy after an acute venous thromboembolism (VTE) depends on the intermediate-term anticoagulant to be used. While heparin bridging to vitamin K antagonists (VKA) is required, the direct oral anticoagulants (DOAC) rivaroxaban (30 mg/day) and apixaban (10 mg/day) can be initiated directly without parenteral anticoagulation. The objective was to evaluate OAC initiation patterns in clinical practice. Materials and methods PREFER in VTE was an international, non-interventional registry conducted between January 2013 and August 2015. Consecutive acute VTE patients were grouped based on their OAC treatment at…

Malemedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanInternal medicinemedicineHumansRegistries030212 general & internal medicineIntensive care medicineLead (electronics)RivaroxabanAnticoagulants; Heparin; Rivaroxaban; Venous thromboembolism; Warfarin; Acute Disease; Anticoagulants; Female; Heparin; Humans; Male; Middle Aged; Registries; Venous Thromboembolism; HematologyHeparinbusiness.industryAnticoagulantWarfarinAnticoagulantsVenous ThromboembolismHematologyHeparinMiddle Agedmedicine.diseasePulmonary embolismAcute DiseaseFemaleApixabanWarfarinbusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct

Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry).

2002

There is conflicting information about gender differences in presentation, treatment, and outcome after acute ST elevation myocardial infarction (STEMI) in the era of thrombolytic therapy and primary percutaneous coronary intervention. From June 1994 to January 1997, we enrolled 6,067 consecutive patients with STEMI admitted to 54 hospitals in southwest Germany in the Maximal Individual TheRapy of Acute myocardial infarction (MITRA), a community-based registry. Women were 9 years older than men, more often had hypertension, diabetes mellitus, and congestive heart failure, and had a history of previous myocardial infarction less often. Women had a longer prehospital delay (45 minutes), had a…

Malemedicine.medical_specialtyEmergency Medical Servicesmedicine.medical_treatmentMyocardial InfarctionInfarctionAngina PectorisAnginaReperfusion therapySex FactorsInternal medicineGermanymedicineHumansThrombolytic TherapyMyocardial infarctionHospital MortalityProspective StudiesRegistriesAgedHeart Failurebusiness.industryPercutaneous coronary interventionThrombolysisOdds ratioMiddle Agedmedicine.diseaseSurvival AnalysisHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessThe American journal of cardiology
researchProduct

Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction

2010

Aims The rate and type of reperfusion, as well as time delays to reperfusion are directly associated with mortality and are established as performance measures (PMs) in the treatment of ST elevation myocardial infarction (STEMI). To date, little information exists about PMs for reperfusion in clinical practice in Europe and their temporal changes. Methods and results Using the Euro Heart Survey ACS-III data set (2 years of inclusions between 2006 and 2008, 138 centres in 21 countries), we selected patients with STEMI eligible for reperfusion therapy. Recorded variables corresponded to the CARDS data set. The rate and type of reperfusion, as well as door to needle and door to artery times we…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionHemorrhageMyocardial ReperfusionReperfusion therapyFibrinolytic AgentsRecurrenceAngioplastyInternal medicinemedicineHumansMyocardial infarctionAngioplasty Balloon CoronaryStrokebusiness.industryST elevationPercutaneous coronary interventionMiddle Agedmedicine.diseaseEuropeHospitalizationStrokeTreatment OutcomeConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFibrinolytic agentEuropean Heart Journal
researchProduct

Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: can we define subgroups of patients benefiting most from primary …

2001

Abstract OBJECTIVES We sought to determine the effectiveness of primary angioplasty compared with thrombolysis in clinical practice. BACKGROUND In clinical practice, primary angioplasty for the treatment of acute myocardial infarction (AMI) has not yet been proven more effective than intravenous thrombolysis, nor have subgroups of patients been identified who would perhaps benefit from primary angioplasty. METHODS The pooled data of two AMI registries—the Maximal Individual TheRapy in Acute myocardial infarction (MITRA) study and the Myocardial Infarction Registry (MIR)—were analyzed. A total of 9,906 lytic-eligible patients with AMI, with a pre-hospital delay of ≤12 h, were treated with ei…

medicine.medical_specialtyUnivariate analysisbusiness.industrymedicine.medical_treatmentAbsolute risk reductionThrombolysisOdds ratiomedicine.diseaseConfidence intervalInternal medicineConcomitantAngioplastyCardiologyMedicineMyocardial infarctionbusinessCardiology and Cardiovascular MedicineJournal of the American College of Cardiology
researchProduct